Antiretroviral treatment in low-resource settings: What has changed in the last 10 years and what needs to change in the coming years?

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 11, 2012, Pages 1287-1296

  Mehta, Mandana ^a   Semitala, Fred ^b   Lynen, Lutgarde ^a   Colebunders, Robert ^a,c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

access to care; antiretroviral therapy; HIV treatment; low resource setting; pre exposure prophylaxis; treatment for prevention

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; COUNSELING; DEVELOPING COUNTRY; DRUG COMBINATION; DRUG COST; ECONOMICS; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; REVIEW;

ANTI-RETROVIRAL AGENTS; COUNSELING; DEVELOPING COUNTRIES; DRUG COSTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEALTH RESOURCES; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE;

EID: 84878775930     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.129     Document Type: Article

References (84)

1. Hogg RS, Anis A, Weber AE, O’Shaughnessy MV, Schechter MT. Triple-combination antiretroviral therapy in sub-Saharan Africa. Lancet 350 (9088), 1406 (1997).
2. Muller O, Corrah T, Katabira E, Plummer F, Mabey D. Antiretroviral therapy in sub-Saharan Africa. Lancet, 351 (9095), 68 (1998).
3. Gilks CF, Katabira E, De Cock KM. The challenge of providing effective care for HIV/AIDS in Africa. AIDS 11 (Suppl. B), S99 – S106 (1997).
4. Vella S, Schwartlander B, Papa Sow S, Eholie SP, Murphy RL. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS 26, 1231 – 1241 (2012).
5. Colebunders R, Karita E, Taelman H, Mugyenyi P. Antiretroviral treatment in Africa. AIDS 11 (Suppl. B), S107 – S113 (1997).
6. Stevens W, Kaye S, Corrah T. Antiretroviral therapy in Africa. BMJ 328 (7434), 280 – 282 (2004).
7. WHO. Global Health Sector Strategy on HIV/AIDS 2011–2015. WHO, Geneva, Switzerland (2011).
8. WHO. Progress Report 2011: Global HIV/AIDS Response. WHO, Geneva, Switzerland (2011).
9. Laurent C, Kouanfack C, Koulla-Shiro S et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 364 (9428), 29 – 34 (2004).
10. Kumarasamy N. Generic antiretroviral drugs – will they be the answer to HIV in the developing world? Lancet 364 (9428), 3 – 4 (2004).
11. WHO. Public Health Approaches to Expand Antiretroviral Treatment. WHO, Geneva, Switzerland (2003).
12. Gilks CF, Crowley S, Ekpini R et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368 (9534), 505 – 510 (2006).
13. Geng EH, Hunt PW, Diero LO et al. Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J. Int. AIDS Soc. 14, 46 (2011).
14. Mugyenyi P, Walker AS, Hakim J et al.; DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375 (9709), 123 – 131 (2010).
15. Emery S, Neuhaus JA, Phillips AN et al.; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J. Infect. Dis. 197 (8), 1133 – 1144 (2008).
16. Siegfried NL, Uthman OA, Rutherfore GW. Optimal time for initiation of antiretroviral therapy for asymptomatic, HIV-infected, treatment-naive adults. Coch. Database Syst. Rev. 3, CD008272 (2010).
17. Severe P, Juste MA, Ambroise A et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N. Engl. J. Med. 363 (3), 257 – 265 (2010).
18. Delva W, Eaton JW, Meng F et al. HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med. 9 (7), e1001258 (2012).
19. Mayer K, Wang L, McCauley M et al. Sustained treatment as prevention: continued decreases in unprotected sex and increases in virological suppression after HAART initiation among participants in HPTN 052. Presented at: XIX International AIDS Conference. Washington, DC, USA, 22–27 July 2012.
20. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations For a Public Health Approach. WHO, Geneva, Switzerland (2010).
21. Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society – USA panel. JAMA 308 (4), 387 – 402 (2012).
22. Kretzschmar M, Schim van der Loeff MF, De Angelis D, Coutinho RA. The prospects of elimination of HIV with test and treat strategy. Presented at: XIX International AIDS Conference. Washington, DC, USA, 22–27 July 2012.
23. Hurt CB, Eron JJ Jr, Cohen MS. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin. Infect. Dis. 53 (12), 1265 – 1270 (2011).
24. Tassie JM, Baijal P, Vitoria MA, Alisalad A, Crowley SP, Souteyrand Y. Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J. Acquir. Immune Defic. Syndr. 54 (4), 437 – 441 (2010).
25. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 8 (7), e1001056 (2011).
26. Posse M, Baltussen R. Barriers to access to antiretroviral treatment in Mozambique, as perceived by patients and health workers in urban and rural settings. AIDS Patient Care STDS 23 (10), 867 – 875 (2009).
27. WHO. The Treatment 2.0 Framework For Action: Catalysing the Next Phase of Treatment, Care and Support. WHO, Geneva, Switzerland (2011).
28. Faal M, Naidoo N, Glencross DK, Venter WD, Osih R. Providing immediate CD4 count results at HIV testing improves ART initiation. J. Acquir. Immune Defic. Syndr. 58 (3), e54 – e59 (2011).
29. Jani IV, Sitoe NE, Alfai ER et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet 378 (9802), 1572 – 1579 (2011).
30. B., Larson, K., Schnippel, B., Ndibongo, et al., Rapid point-of-care CD4 testing at mobile HIV testing sites to increase linkage to care: an evaluation of a pilot program in South Africa, J. Acquir. Immune Defic. Syndr., doi:10.1097/QAI.0b013e31825eec60 (Epub ahead of print)., (2012)
31. Pai NP, Pai M. Point-of-care diagnostics for HIV and tuberculosis: landscape, pipeline and unmet needs. Discov. Med. 13 (68), 35 – 45 (2012).
32. Murtagh M. UNITAID Technical Report. HIV/AIDS Diagnostic Landscape. UNITAID, Geneva, Switzerland (2011).
33. Kipp W, Konde-Lule J, Rubaale T, Okech-Ojony J, Alibhai A, Saunders DL. Comparing antiretroviral treatment outcomes between a prospective community-based and hospital-based cohort of HIV patients in rural Uganda. BMC Int. Health Hum. Rights 11 (Suppl. 2), S12 (2011).
34. Lugada E, Levin J, Abang B et al. Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomised trial. AIDS 55 (2), 254 – 252 (2010).
35. Thompson MA, Mugavero MJ, Amico KR et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann. Intern. Med. 156 (11), 817 – 833 (2012).
36. Callaghan M, Ford N, Schneider H. A systematic review of task- shifting for HIV treatment and care in Africa. Hum. Resour. Health 8, 8 (2010).
37. Wandeler G, Keiser O, Pfeiffer K et al.; SolidarMed ART program and IeDEA-Southern Africa. Outcomes of antiretroviral treatment programs in rural Southern Africa. J. Acquir. Immune Defic. Syndr. 59 (2), e9 – e16 (2012).
38. Mukund Bahadur KC, Murray PJ. Cell phone short messaging service (SMS) for HIV/AIDS in South Africa: a literature review. Stud. Health Technol. Inform. 160 (Pt 1), 530 – 534 (2010).
39. Cole-Lewis H, Kershaw T. Text messaging as a tool for behavior change in disease prevention and management. Epidemiol. Rev. 32 (1), 56 – 69 (2010).
40. Amoroso CL, Akimana B, Wise B, Fraser HS. Using electronic medical records for HIV care in rural Rwanda. Evid. Rep. Technol. Assess 160 (1), 337 – 341 (2006).
41. Mulissa Z, Jerene D, Lindtjørn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS ONE 5 (10), e13268 (2010).
42. Lahuerta M, Lima J, Nuwagaba-Biribonwoha H et al. Factors associated with late antiretroviral therapy initiation among adults in Mozambique. PLoS ONE 7 (5), e37125 (2012).
43. Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H. Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. J. Acquir. Immune Defic. Syndr. 43 (Suppl. 1), S123 – S126 (2006).
44. Rich ML, Miller AC, Niyigena P et al. Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. J. Acquir. Immune. Defic. Syndr. 59 (3), e35 – e42 (2012).
45. Koole O, Tsui S, Wabwire-Mangen F et al. Retention and risk factors for attrition among adults in antiretroviral treatment (ART) programs in Tanzania, Uganda and Zambia. Presented at: XIX International AIDS Conference. Washington DC, USA, 22–27 July 2012.
46. Burtle D, Welfare W, Elden S et al. Introduction and evaluation of a ‘pre-ART care’ service in Swaziland: an operational research study. BMJ Open 2, e000195 (2012).
47. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect. Dis. 11 (12), 942 – 951 (2011).
48. Lima VD, Bangsberg D, Harrigan PR et al. Risk of viral failure declines with duration of suppression on HAART, irrespective of adherence level. J. Acquir. Immun. Defic. Synd. 55 (4), 460 – 465 (2011).
49. Mills EJ, Nachega JB, Bangsberg DR et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 3 (11), e438 (2006).
50. Decroo T, Van Damme W, Kegels G, Remartinez D, Rasschaert F. Are expert patients an untapped resource for ART provision in sub-Saharan Africa? AIDS Res Treat doi:10.1155/2012/749718 (2012) (Epub ahead of print).
51. Hamers RL, Wallis CL, Kityo C et al.; PharmAccess African Studies to Evaluate Resistance (PASER). HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect. Dis. 11 (10), 750 – 759 (2011).
52. Price MA, Wallis CL, Lakhi S et al.; IAVI Early Infection Cohort Study Group. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res. Hum. Retroviruses 27 (1), 5 – 12 (2011).
53. Ndembi N, Lyagoba F, Nanteza B et al.; Uganda HIV Drug Resistance Working Group. Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res. Hum. Retroviruses 24 (6), 889 – 895 (2008).
54. Wittkop L, Günthard HF, de Wolf F et al.; EuroCoord–CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord–CHAIN joint project): a European multicohort study. Lancet Infect. Dis. 11 (5), 363 – 371 (2011).
55. Keiser O, Chi BH, Gsponer T et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. AIDS 25, 1761 – 1769 (2011).
56. Taiwo B, Murphy RL, Katlama C. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results. Drugs 70 (13), 1629 – 1642 (2010).
57. Schito M, Peter TF, Cavanaugh S et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J. Infect. Dis. 205 (Suppl. 2), S169 – S180 (2012).
58. Violari A, Cotton MF, Gibb DM et al.; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359 (21), 2233 – 2244 (2008).
59. Lyons C, Mushavi A, Ngobeni-Allen F, Yule R, Abrams E. Ending paediatric AIDS and achieving a generation born HIV-free. J. Acquir. Immune Defic. 60 (Suppl. 2), S35 – S38 (2012).
60. Baeten JM, Donnell D, Ndase P et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367 (5), 399 – 410 (2012).
61. Ware NC, Wyatt MA, Haberer JE et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J. Acquir. Immune Defic. Syndr. 59 (5), 463 – 468 (2012).
62. Person AK, Hicks CB. Pre-exposure prophylaxis – one more tool for HIV prevention. Curr. HIV Res. 10 (2), 117 – 122 (2012).
63. Hallett TB, Baeten JM, Heffron R et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 8 (11), e1001123 (2011).
64. Hermans SM, Castelnuovo B, Katabira C et al. Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. J. Acquir. Immune Defic. Syndr. 60 (2), e29 – e35 (2012).
65. Reid A, Scano F, Getahun H et al. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect. Dis. 6 (8), 483 – 495 (2006).
66. Phiri S, Khan PY, Grant AD et al. Integrated tuberculosis and HIV care in a resource-limited setting: experience from the Martin Preuss centre, Malawi. Trop. Med. Int. Health 16 (11), 1397 – 1403 (2011).
67. Isaakidis P, Cox HS, Varghese B et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS ONE 6 (12), e28066 (2011).
68. Howard AA, El-Sadr WM. Integration of tuberculosis and HIV services in sub-saharan Africa: lessons learned. Clin. Infect. Dis. 50 (Suppl. 3), S238 – S244 (2011).
69. Zachariah R, Tayler-Smith K, Manzi M et al. Retention and attrition during the preparation phase and after start of antiretroviral treatment in Thyolo, Malawi, and Kibera, Kenya: implications for programmes? Trans. R. Soc. Trop. Med. Hyg. 105 (8), 421 – 430 (2011).
70. Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J. Acquir. Immune Defic. Syndr. 56 (3), e79 – e86 (2011).
71. Lubega M, Nsabagasani X, Tumwesigye NM et al. Policy and practice, list in transition: reasons for high drop-out from pre-antiretroviral care in a resource poor setting of eastern Uganda. Health Policy 95 (2–3), 153 – 158 (2009).
72. Muhamadi L, Tumwesigye NM, Kadobera D et al. Lack of pre-antiretroviral care and competition from traditional healers, crucial risk factors for very late initiation of antiretroviral therapy for HIV – a case–control study from eastern Uganda. Pan Afr. Med. J. 8, 40 (2011).
73. Muhamadi L, Tumwesigye NM, Kadobera D et al. A single-blind randomized controlled trial to evaluate the effect of extended counseling on uptake of pre-antiretroviral care in Eastern Uganda. Trials 12, 184 (2011).
74. Grant RM, Lama JR, Anderson PL et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363 (27), 2587 – 2599 (2010).
75. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al.; CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329 (5996), 1168 – 1174 (2010).
76. Bautista-Arredondo S, Martz TE, Wirtz VJ, Bertozzi SM. Optimizing HIV treatment programs. Curr. Opin. HIV AIDS 5 (3), 232 – 236 (2010).
77. Kunutsor S, Walley J, Katabira E et al. Improving clinic attendance and adherence to antiretroviral therapy through a treatment supporter intervention in Uganda: a randomized controlled trial. AIDS Behav. 15 (8), 1795 – 1802 (2011).
78. Waters L. HIV therapy past, present and future. www.ddw-online.com/s/therapeutics/p92867/hiv-therapy-pastpresent-and-future-summer-08.html
79. WHO. Antiretroviral treatment as prevention of HIV and TB: a 2012 update. WHO, Geneva, Switzerland. http://whqlibdoc.who.int/hq/2012/WHO_HIV_2012.12_eng.pdf
80. ClinicalTrials.gov. Strategic Timing of Antiretroviral Treatment (START). ClinicalTrials.gov identifier: NCT00867048. http://clinicaltrials.gov/ct2/show/NCT00867048
81. ClinicalTrials.gov. Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO). ClinicalTrials.gov identifier: NCT00495651. http://clinicaltrials.gov/show/NCT00495651
82. London School of Hygiene and Tropical Medicine. ZAMSTAR project reduces prevalence of tuberculosis by 22%. www.news-medical.net/news/20111031/ZAMSTAR-project-reduces-prevalence-of-tuberculosis-by-2225.aspx
83. WHO. Antiretroviral treatment as prevention of HIV and TB. Programmatic update. http://whqlibdoc.who.int/hq/2012/WHO_HIV_2012.12_eng.pdf
84. WHO. Rapid advice. Antiretroviral therapy for HIV infection in adults and adolescents. WHO, Switzerland, Geneva. www.who.int/hiv/pub/arv/rapid_advice_art.pdf on